Navigation Links
Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
Date:11/23/2009

SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U'Prichard have agreed to join the Anesiva board of directors following completion of the proposed merger between Anesiva and Arcion Therapeutics. Completion of the merger is subject to a shareholder vote scheduled to take place at the previously announced Anesiva 2009 Annual Meeting of Stockholders, to be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California, among other conditions.

"We are very pleased to be able to recruit directors of this caliber. Their talents will be important as we make plans to move our new company forward after the merger," said Michael Kranda, president and chief executive officer of Anesiva.

"Maintaining governance requirements and a qualified NASDAQ listing is a high priority for the merged companies and these gentlemen will bring excellent experience to our board," said Dr. Arnold Oronsky, director of Anesiva and Arcion Therapeutics.

From 2001 to 2009, Dr. Love served as president, chief executive officer and director of Nuvelo, Inc., a biopharmaceutical company, and as chairman of the company's board of directors from 2005 to 2009, prior to its merger with ARCA Biopharma, Inc. From 1998 to 2001, Dr. Love served as senior vice president of development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, Dr. Love served as a research physician and vice president of product development at Genentech, Inc. Dr. Love also serves as member of the board of directors of Santarus, ARCA and Affymax. Dr. Love holds an M.D. from Yale medical school and a B.A. from Haverford College.

Dr. U'Prichard currently serves as president of Druid Consulting LLC and as a ven
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
2. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
9. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... July 27, 2011 Pharmaceutics International, Inc. (Pii), a ... it has added hot melt extrusion (HME) to its ... has purchased a 16mm and an 18mm Leistritz twin ... feasibility studies, using just a few grams of active ...
... Pharmaceuticals, Inc., announced today that the company has ... Angel Investors. The company is using the capital ... orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for ... arthritis, multiple sclerosis, psoriasis and COPD. ...
Cached Medicine Technology:Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology 2Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 “North ... key market data on the North America Contrast Media ... US dollars, and volume (in units) and average price ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and ... (or contrast agent) is a substance used to enhance ...
(Date:7/30/2014)... for Vedic Studies (WAVES) conference is coming to Fairfield, ... 31 through Sunday, August 3. To watch the main ... the first time such a large and diverse group ... to explore the relevance of ancient Vedic knowledge in ... states of consciousness, and reflections on the various Vedic ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis ... Directors of the American Telemedicine Association (ATA). ... has a mission to promote professional, ethical and ... information technology. , “Both Naomi Fried and Alexis ... expertise and are well known experts in their ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... to suffer from depression as school-age children and young ... times more likely to suffer from the condition in ... depressed at very young ages, according to researchers at ... Their study is published in the July issue of ... the same old bad news about depression; it is ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... ... movies for presentations, demonstrations and training. Version 7.5 introduces TrakMouse™, a new technology that ... , ... July 9, 2009 -- NetPlay Software releases Instant Demo v7.5 , a Windows ...
... Hollywood impact radiation perception? Can we treat cancer with ... the radiation exposure our astronauts receive during space travel ... and other questions will be addressed at the 54th ... will take place July 13-16, 2009 in Minneapolis, MN, ...
... ... change the law regarding personal injury accidents, New York personal injury lawyer David Perecman weighs ... New York, New ... Authority (MTA) spends millions to pay for damages caused to riders., , , , ,Unfortunately ...
... MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) announced today ... the Company,s existing Common Stock Purchase Warrants with Initial Exercise ... Warrants") for newly issued Common Stock Purchase Warrants with a ... one-half the original number of shares of our common stock, ...
... TROIS-RIVIERES, Quebec, July 8 The Narconon drug rehab program ... with drug related charges due to their addiction. "You ... drug addiction, and just one day gets caught by police ... representative of Narconon Trois-Rivieres. "This is an all too ...
... Today, the American Hospital Association, Federation of American Hospitals ... White House and Senate Finance Chairman Max Baucus (D-MT) ... Cost savings is an important goal, supported by Physician ... owned hospitals. As always, physician hospitals will shoulder their ...
Cached Medicine News:Health News:Instant Demo Screen Recorder Now With TrakMouse™ Technology 2Health News:Health Physics Society 54th Annual Meeting 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 3Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Drug Crimes in Canada Cause Continuing Problems for Small Communities 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation....
Medicine Products: